Cancer Care · global
Adding Immunotherapy After Surgery for Stage III dMMR Colon Cancer Halves Risk of Recurrence or Death in Trial
The FDA has approved atezolizumab plus chemotherapy for postoperative treatment in certain patients with colon cancer. Three-year disease-free survival rose from approximately 76% to 86%, but the benefit applies to patients with deficient DNA mismatch repair, and immune-related side effects must also be weighed.
Reducing the chance of cancer returning after tumor removal is a key challenge in colon cancer treatment. For patients with stage III colon cancer and deficient DNA mismatch repair (dMMR), a large trial has provided evidence supporting the addition of immunotherapy after surgery: combining atezolizumab with chemotherapy reduced the risk of recurrence or death compared with chemotherapy alone. The U.S. Food and Drug Administration (FDA) approved this use on October 8, 2026.
The approval covers atezolizumab (brand name Tecentriq) in combination with a fluoropyrimidine and oxaliplatin. Roche said this is the first approved adjuvant immunotherapy regimen for stage III dMMR colon cancer. Eligibility depends on the tumor’s molecular characteristics and cannot be directly extended to all patients with colon cancer.
dMMR refers to defects in the cellular mechanisms that repair errors in DNA replication, causing tumors to accumulate more mutations and potentially making them easier for the immune system to recognize. Atezolizumab is an antibody targeting PD-L1 that helps restore T cells’ antitumor activity by blocking signals that suppress immune responses. This allows postoperative treatment to address potentially remaining cancer cells while also taking advantage of the biological characteristics of these tumors.
The phase III ATOMIC trial supporting the approval enrolled 712 patients who had undergone tumor removal and randomly assigned them to two groups. One group received mFOLFOX6 chemotherapy plus atezolizumab, while the other received mFOLFOX6 alone. This chemotherapy regimen consists of oxaliplatin, leucovorin and fluorouracil. The trial used an open-label design, with investigator-assessed disease-free survival as the primary endpoint.
The FDA reported a hazard ratio for disease-free survival of 0.50, with a 95% confidence interval of 0.35 to 0.73 and a p-value of 0.0001. Roche separately reported that three-year disease-free survival was approximately 86% in the combination group and approximately 76% in the chemotherapy group, a difference of about 10 percentage points. Thus, a “50% reduction in risk” describes the relative risk during follow-up; it does not mean that 50 fewer patients out of every 100 experienced recurrence or death. Median disease-free survival had also not yet been reached in either group, and these results cannot be directly equated with an established improvement in overall survival.
The treatment also entails a longer period of drug therapy. The combination group first received approximately six months of immunotherapy and chemotherapy, followed by approximately six months of atezolizumab alone. The FDA noted that the drug’s warnings cover immune-mediated adverse reactions, infusion-related reactions and embryo-fetal toxicity. Roche said the safety profile was consistent with previous studies, but this announcement did not provide complete adverse event rates, leaving insufficient information to precisely compare safety differences between the two groups.
This approval provides a new postoperative treatment option selected according to molecular characteristics for certain patients with colon cancer, while also highlighting the importance of determining a tumor’s mismatch repair status. Roche said it is pursuing additional applications, including with the European Medicines Agency. Approval in the United States does not mean that use has been authorized simultaneously in other regions.